Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
The FDA has stated explicitly that "retatrutide and cagrilintide cannot be used in compounding under federal law." The reason is that retatrutide does not appear on the 503A bulks list, is not a component of any FDA-approved drug, and does not have an applicable USP or NF monograph
Quick comparison: Peak is roughly $3,900 cheaper per year for cash-pay patients on the 6-month plan ($1,980 vs $5,866)
doi: 10.1038/s41598-021-88612-x Liang L, Su X, Guan Y, Wu B, Zhang X, Nian X
Lot B2416 matched the posted certificate exactly
New iterations have been rolling out ever since
Is the powder still dry and compact, or has it shifted or clumped (suggesting moisture exposure)
US$ 20.32
US$ 29.14
US$ 24.80
